JPRN-jRCT2031220356进行中（未招募）3 期
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis
Shikamura Mitsuhiro0 个研究点目标入组 5 人开始时间: 2022年10月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1month old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.The participant is Japanese male or female with a body weight >=3.0 kg and who is >=1 month of age at the time of informed consent.
- •2.The participant has a cholestasis as manifested by total serum bile acid (sBA) >=3^ upper limit of the normal range (ULN) (applies to the primary cohort only).
- •3.The participant has an average morning ItchRO (Obs) score >=1.5 during 4 consecutive weeks of the screening period, leading to the baseline visit (Week 0/Visit 2). Since it is difficult to evaluate pruritus in infants, participants <12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.
- •4.The caregiver has completed at least 21 valid* morning ItchRO (Obs) entries during 4 consecutive weeks of the screening period, leading to the baseline visit (Week 0/Visit 2) (*valid=completed and not answered as I don't know; the maximum allowed invalidreports=7, no more than 2 invalid reports during the last 7 days before the baseline visit [Week 0/Visit 2]).
- •5.The participant has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) based on:
- •Chronic cholestasis as manifested by persistent (>6 months*) pruritus in addition to biochemical abnormalities and/or pathological evidence of progressive liver disease (* =<6 months is acceptable for participants <12 months of age).
- •For Primary cohort:
- •a) The participant has a genetic testing result consistent with disease-causing variation in ABCB11 (PFIC2), based on a genotyping.
- •For Supplemental cohort:
- •a) The participant has a genetic testing results consistent with disease causing variation in ATP8B1 (PFIC1), ABCB4 (PFIC3), or tight junction protein 2 gene (TJP2) (PFIC4), based on a genotyping.
- •b) The participant has a PFIC phenotype without a known mutation or with another known mutation not described above.
- •c) The PFIC participant has internal or external biliary diversion surgery history, and the internal or external biliary diversion surgery was reversed.
- •6.The participant (whenever possible) and caregiver are able to be contacted by phone for scheduled remote visits (participant contacts [phone calls]).
- •7.Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
- •8.The same caregiver should be contacted during this study. The ItchRO (Obs) should be completed by the same caregiver for consistency during this study, even if the participant is an adult (over 18 years old).
排除标准
- •1.The diagnosed with PFIC2 due to ABCB11 mutation that predicts complete absence of BSEP function due to the type of ABCB11 mutation (t-PFIC2), based on a genotyping (applies to the primary cohort only).
- •2.The participant has a diagnosis of benign recurrent intrahepatic cholestasis indicated by a history of intermittent cholestasis with no disease progression.
- •3.The participant has a current or recent history (<1 year) of atopic dermatitis or other non-cholestatic diseases associated with pruritus.
- •4.The participant has a previous history of surgical interruption of the enterohepatic circulation (applies to the primary cohort only).
- •5.The participant with chronic diarrhea requiring intravenous (IV) fluid or nutritional intervention and/or its sequelae at screening or during the 6 months prior to screening.
- •6.The participant has a history of liver transplant or currently requires imminent liver transplant.
- •7.The participant with decompensated cirrhosis (international normalized ratio [INR] >1.5, and/or albumin <30 g/L, history, or presence of clinically significant ascites, and/or variceal hemorrhage, and/or encephalopathy).
- •8.The participant has an alanine aminotransferase (ALT) or total serum bilirubin (TSB) level >15^ ULN at screening.
- •9.The participant has other liver disease.
- •10.The participant has any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease), per investigator discretion.
- •11.The participant has a possible malignant liver mass in imaging, including screening ultrasound.
- •12.The participant has received bile acid, lipid binding resins or ileal bile acid transporter (IBAT) inhibitors within 28 days prior to screening and throughout the trial.
- •13.The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.
研究者
相似试验
进行中（未招募）
3 期
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)Alagille Syndrome (ALGS)JPRN-jRCT2051220098Shikamura Mitsuhiro7
招募中
3 期
A Study of Vedolizumab, given every 4 weeks, in Japanese Participants with Moderate to Severe Ulcerative Colitis or Crohn's Diseaselcerative Colitis, Crohn's DiseaseJPRN-jRCT2031200371Shikamura Mitsuhiro158
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry DiseaseFabry diseaseMedDRA version: 24.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-004689-32-PLShire Human Genetic Therapies, Inc.36
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry DiseaseFabry diseaseEUCTR2018-004689-32-SEShire Human Genetic Therapies, Inc.45
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry DiseaseREPLAGAL is intended for use for patients with Fabry disease.MedDRA version: 24.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-004689-32-FIShire Human Genetic Therapies, Inc.45